Abbott Laboratories (ABT)
| Market Cap | 201.45B -11.5% |
| Revenue (ttm) | 44.33B +5.7% |
| Net Income | 6.50B -51.3% |
| EPS | 3.72 -51.3% |
| Shares Out | 1.74B |
| PE Ratio | 31.16 |
| Forward PE | 20.41 |
| Dividend | $2.52 (2.17%) |
| Ex-Dividend Date | Apr 15, 2026 |
| Volume | 4,093,544 |
| Open | 115.32 |
| Previous Close | 114.76 |
| Day's Range | 114.51 - 116.53 |
| 52-Week Range | 105.27 - 141.23 |
| Beta | 0.75 |
| Analysts | Strong Buy |
| Price Target | 141.00 (+21.63%) |
| Earnings Date | Apr 15, 2026 |
About ABT
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism,... [Read more]
Financial Performance
In 2025, Abbott Laboratories's revenue was $44.33 billion, an increase of 5.67% compared to the previous year's $41.95 billion. Earnings were $6.50 billion, a decrease of -51.49%.
Financial StatementsAnalyst Summary
According to 18 analysts, the average rating for ABT stock is "Strong Buy." The 12-month stock price target is $141.0, which is an increase of 21.63% from the latest price.
News
Abbott's Meltdown Is Worth Buying, Compelling, Profitable Growth Prospects
Abbott's Meltdown Is Worth Buying, Compelling, Profitable Growth Prospects
Exact Sciences Stockholders Approve Acquisition by Abbott
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corporation (NASDAQ: EXAS) (“Exact Sciences”), a leading provider of cancer screening and diagnostic tests, today announced that its stockholders voted t...
Abbott declares 409th consecutive quarterly dividend
ABBOTT PARK, Ill., Feb. 20, 2026 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 63 cents per share.
Carl Abbott's “House of Columns” Brings Sarasota School Modernism to the Market on Longboat Key
LISTING LINK: https://www.premiersothebysrealty.com/single-family/mfr/a4681242/6610-gulf-of-mexico-drive-longboat-key-fl-34228 DROPBOX: https://tours.coastalhomephotography.net/public/vtour/display/23...
Baron Discovery Fund Q4 2025: Winners, Laggards, Buys & Sells
In the fourth quarter of 2025, the Baron Discovery Fund returned 0.19% (Institutional Shares), trailing the Russell 2000 Growth Index by 1.03%. In these periods, low quality (high debt and poor profit...
Late-breaking data presentations showcase the safety and efficacy of Abbott's ablation catheters to treat people with atrial fibrillation
Positive 12-month results from the VOLT-AF IDE Study presented at the AF Symposium and simultaneously published in JACC: Clinical Electrophysiology, reinforce the Volt™ Pulsed Field Ablation (PFA) Sys...
Abbott recalls glucose sensors after seven deaths linked to faulty readings
Abbott has recalled certain glucose monitoring sensors after reports linked the devices to seven deaths and 860 serious injuries, the U.S. health regulator said on Wednesday.
Abbott: Long-Term Investment Opportunity For Dividend Growth Investors
In reality, Abbott Laboratories is actually a Dividend Aristocrat – a vaunted status reserved for companies that have increased dividends for at least 25 consecutive years. ABT grew its revenue from $...
10 Highest Rated Dividend Kings For Generations Of Income
My top 10 Dividend Kings list prioritizes reliability, dividend safety, and attractive valuation for long-term, generational income. Selection criteria include payout ratios under 70%, strong dividend...
Best Dividend Kings: January 2026
Dividend Kings underperformed SPY in 2025, averaging 4.91% total return versus SPY's 17.72%, though 14 Kings outperformed the index. 2026 began strongly for Dividend Kings, up 4.66% through January 23...
Abbott Laboratories: Double-Digit Earnings Growth Makes It A Buy
Abbott Laboratories is rated 'Buy,' following a recent price drop, driven by Nutrition segment weakness and COVID-19 diagnostics decline. ABT's Medical Devices segment, especially CGM, continues to de...
Abbott Laboratories: The Market's Overreaction Is The Long-Term Investor's Opportunity
Abbott Laboratories experienced a post-earnings sell-off driven by weakness in its Nutrition segment and a sizable revenue miss. Despite segment headwinds, ABT delivered double-digit bottom-line growt...
Is The Fall In Abbott Stock Justified?
Abbott Laboratories reported Q4 2025 sales of $11.46 billion, an increase of 4.4% from the previous year but falling short of analyst projections by approximately 3%. The adjusted EPS was $1.50, align...
Abbott Laboratories: Buy This Dividend King On Sale Now
Last month, Abbott Laboratories hiked its dividend for the 54th consecutive year. The company's FreeStyle Libre and Volt PFA System franchises, as well as its pending acquisition of Exact Sciences, po...
Abbott faces India scrutiny in cough syrup abuse investigation, documents show
Indian drugmaker Abbott Healthcare's supply chain is being scrutinised as part of a wider investigation into the alleged misuse of its codeine-based cough syrup which is prone to abuse by addicts, doc...
Abbott Laboratories Raised Prices, Prompting Sales Slump
The medical-products maker's shares tumbled after its quarterly profit and sales underwhelmed investors.
Abbott Laboratories (ABT) Q4 2025 Earnings Call Transcript
Abbott Laboratories (ABT) Q4 2025 Earnings Call Transcript
Crude Oil Down 2%; Abbott Shares Fall Following Q4 Results
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 200 points on Thursday.
MRNA Rallies on Cancer Vaccine Trial, PG Mixed Earnings, ABT Sell-Off
Intel's (INTC) recent rally isn't the only one investors should pay attention to, says Diane King Hall. She points to Moderna (MRNA) hitting a 52-week high after a trial drug to treat melanoma posted ...
Cramer's Mad Dash: Abbott Labs
CNBC's Jim Cramer delivers his daily Mad Dash.
Abbott Labs Stock Hits 52-Week Low As Outlook Disappoints
Abbott Laboratories (NYSE: ABT) stock fell on Thursday after the company reported fourth-quarter 2025 sales and the first-quarter 2026 earnings outlook below expectations.
Abbott Stock Slumps on Earnings. What's Weighing on the Medical Devices Maker.
Abbott reports fourth-quarter sales that miss analysts' estimates.
Abbott misses quarterly revenue estimates on weakness in diagnostics segment
Abbott missed Wall Street estimates for quarterly revenue on Thursday, hit by weakness in its diagnostic business which has been volatile due to sharp decline in COVID-19 testing demand and a freeze o...
Abbott Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Financial Outlook
Fourth-quarter GAAP diluted EPS of $1.01; adjusted diluted EPS of $1.50 reflects growth of 12 percent Full-year 2025 GAAP diluted EPS of $3.72; adjusted diluted EPS of $5.15 reflects growth of 10 perc...